Literature DB >> 25208557

Molecular simulation of Tyr105 phosphorylated pyruvate kinase M2 to understand its structure and dynamics.

Ponnusamy Kalaiarasan1, Naidu Subbarao, Rameshwar Nk Bamezai.   

Abstract

Tyrosine phosphorylation (p-Y105) of pyruvate kinase (PK) M2, in recent years, has been suggested to facilitate Warburg effect and tumor cell growth. However, a comparison of the structural dynamics of the un-phosphorylated, the active, and the phosphorylated-at-Y105, the inactive-states, is not clear. We studied molecular dynamics of the two states to unravel these features, where phosphorylated PKM2 showed a rapid global conformation change in the initial stages of the simulation. The overall simulation identified that the phosphorylation event results in more buried and less flexible PKM2 conformation, as compared to the un-phosphorylated form, resulting in an open and closed conformation of the active site in un-phosphorylated and phosphorylated forms, respectively, due to the movement of B domain. This conformational shift in Y105-phosphorylated-PKM2 (p-Y105-PKM2) with closed active site, responsible for inhibition of PKM2 activity, was an outcome of the bending residues (117-118, 218-219, 296-297, and 301-308) within the loop connecting A and B domains and the presence of helix-loop-helix motif in A domain. The un-phosphorylated PKM2 formed a helix bend (H4) due to less fluctuation of the residue S-100; where the other end of the helix (H4) was connected to the substrate binding pocket. Further, simulation analysis showed that phosphorylation did not affect the FBP binding predominantly. We propose that p-Y105 inhibits the activity of PKM2 without influencing FBP binding directly and not allowing the open binding conformation by influencing G128, S100, G506 and gamma turn, G126 and S127 residues. Phosphorylated PKM2 was also identified to gain the transcriptional factor function which was not the case with un-phosphorylated form. These structurally important residues in PKM2 could have a bearing on cancer metabolism, since PKM2 has been implicated in the promotion of cancer in the recent past.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25208557     DOI: 10.1007/s00894-014-2447-6

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  20 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  PKM2: a gatekeeper between growth and survival.

Authors:  Isaac Harris; Susan McCracken; Tak Wah Mak
Journal:  Cell Res       Date:  2011-12-20       Impact factor: 25.617

3.  Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme.

Authors:  S Hayward; H J Berendsen
Journal:  Proteins       Date:  1998-02-01

4.  Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis.

Authors:  Jill D Dombrauckas; Bernard D Santarsiero; Andrew D Mesecar
Journal:  Biochemistry       Date:  2005-07-12       Impact factor: 3.162

5.  Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses.

Authors:  Dimitrios Anastasiou; George Poulogiannis; John M Asara; Matthew B Boxer; Jian-kang Jiang; Min Shen; Gary Bellinger; Atsuo T Sasaki; Jason W Locasale; Douglas S Auld; Craig J Thomas; Matthew G Vander Heiden; Lewis C Cantley
Journal:  Science       Date:  2011-11-03       Impact factor: 47.728

Review 6.  Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Authors:  Hua Yu; Marcin Kortylewski; Drew Pardoll
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

7.  Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1.

Authors:  Weibo Luo; Hongxia Hu; Ryan Chang; Jun Zhong; Matthew Knabel; Robert O'Meally; Robert N Cole; Akhilesh Pandey; Gregg L Semenza
Journal:  Cell       Date:  2011-05-27       Impact factor: 41.582

8.  Tumor M2-pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring.

Authors:  Joachim Schneider; Kathleen Neu; Helmut Grimm; Hans-Georg Velcovsky; Gunter Weisse; Erich Eigenbrodt
Journal:  Anticancer Res       Date:  2002 Jan-Feb       Impact factor: 2.480

9.  Dominant negative mutations affect oligomerization of human pyruvate kinase M2 isozyme and promote cellular growth and polyploidy.

Authors:  Vibhor Gupta; Ponnusamy Kalaiarasan; Mohammad Faheem; Nishant Singh; Mohammad Askandar Iqbal; Rameshwar N K Bamezai
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

10.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

View more
  3 in total

1.  Moderate DNA damage promotes metabolic flux into PPP via PKM2 Y-105 phosphorylation: a feature that favours cancer cells.

Authors:  Bhupender Kumar; Rameshwar N K Bamezai
Journal:  Mol Biol Rep       Date:  2015-04-04       Impact factor: 2.316

2.  IGF1 regulates PKM2 function through Akt phosphorylation.

Authors:  Barbara Salani; Silvia Ravera; Adriana Amaro; Annalisa Salis; Mario Passalacqua; Enrico Millo; Gianluca Damonte; Cecilia Marini; Ulrich Pfeffer; Gianmario Sambuceti; Renzo Cordera; Davide Maggi
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Increased SUMO-activating enzyme SAE1/UBA2 promotes glycolysis and pathogenic behavior of rheumatoid fibroblast-like synoviocytes.

Authors:  Cuicui Wang; Youjun Xiao; Minxi Lao; Jingnan Wang; Siqi Xu; Ruiru Li; Xuanxian Xu; Yu Kuang; Maohua Shi; Yaoyao Zou; Qingwen Wang; Liuqin Liang; Song Guo Zheng; Hanshi Xu
Journal:  JCI Insight       Date:  2020-09-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.